南京地区34家医院2010-2012年双膦酸盐类药物应用分析  

Analysis of the Utilization of Bisphosphonates Drugs in 34 Hospitals from Nanjing Area during 2010-2012

作　　者：钱珊珊[1] 秦利荣[1] 戴惠珍[2] 

机构地区：[1]南京大学医学院附属鼓楼医院药学部,南京210008 [2]江苏省医学情报研究所,南京210004

出　　处：《中国药房》2014年第22期2029-2031,共3页China Pharmacy

摘　　要：目的:了解双膦酸盐类药物的使用状况及趋势。方法:采用世界卫生组织推荐的限定日剂量为指标的分析方法,对南京地区34家医院2010-2012年的双膦酸盐类药物的销售金额、用药频度(DDDs)和日均费用(DDC)等进行统计、分析。结果:双膦酸盐类药物销售金额和DDDs逐年增加,销售金额平均增幅达25.5%,DDDs以年均14%的速度增长,DDC处于稳中略降的态势。双膦酸盐氯屈膦酸由于口服方便、价格便宜,市场占有率依然较高,2012年销售金额占10.65%。临床安全性和疗效方面更佳的第三代双膦酸盐占据了主要市场,以唑来膦酸(2012年销售金额占63.81%)和阿仑膦酸钠(2012年销售金额占12.59%)为主。结论:双膦酸盐类药物在骨吸收相关性疾病中的应用逐渐受到重视,第二代和第三代双膦酸盐已经占据了主要市场。OBJECTIVE： To investigate the utilization and trend of bisphosphonates drugs. METHODS： Using.defined daily dose （DDD） index recommended by WHO, the utilization of bisphosphonates drugs in 34 hospitals from Nanjing area during 2010--2012 were analyzed statistically in terms of consumption sum, DDDs and DDC. RESULTS： Annual consumption sum and DDDs of bisphosphonates drugs increased by 25.5 % and 14% respectively, while DDC kept slight decrease yearly. Bisphosphonate elodronate obtained high market share （more than 10.65% in 2012） since convenient oral and cheap cost; contribute to sally and better effect, the third-generation bisphosphonate occupied the main market, mainly including zoledronic acid （market share of 63.81% ,2012） and alendronate （market share of 12.59%, 2012）. CONCLUSIONS： Bisphosphonates drugs have been gradually appreiated in the treatment of bone resorption and associated diseases. The second-and third-generation bisphosphonates have occupied the main market share.

关 键 词：双膦酸盐类药物 限定日剂量 用药频度 

分 类 号：R969.3[医药卫生—药理学] R97[医药卫生—药学]